Efficacy of the Retrograde Popliteal Approach in Treating Flush Occlusion of the Superficial Femoral Artery

Abstract

Flush occlusion of the superficial femoral artery (SFA) presents a significant challenge in endovascular interventions due to the complex anatomical location and limited access points. The retrograde popliteal  Approach has emerged as a viable technique for revascularization in such cases. This review aims to evaluate the efficacy, safety, and technical success of the contralateral antegrade approach in managing flush occlusions of the SFA. The analysis includes data from recent studies, clinical trials, and expert consensus, highlighting outcomes, procedural complications, and patient prognosis. Flush occlusion of the superficial femoral artery represents a severe peripheral arterial disease manifestation, often resulting in critical limb ischemia and significant morbidity. Traditional endovascular techniques face challenges due to the occlusion's proximity to the arterial bifurcation, making antegrade access difficult. The contralateral antegrade approach, utilizing femoral access from the unaffected side, offers an alternative route for crossing and treating these challenging lesions. But in some morphological challenging occlusions as flush SFA we still need a valid alternative other than ante-grade of contralateral crossover access. The retrograde approach demonstrated high technical success rates. Procedural time was generally shorter compared to retrograde techniques. Complication rates, including arterial dissection and access site hematoma, remained low. Key factors contributing to success included operator experience, lesion length, and the use of advanced crossing devices. Additionally, patients showed significant improvement in ankle-brachial index (ABI) and symptom relief post-procedure. Conclusion The retrograde popliteal approach is a safe and effective technique for treating flush occlusions of the superficial femoral artery. It offers high technical success rates and favorable patient outcomes while minimizing complications. Further randomized controlled trials are needed to validate these findings and refine procedural guidelines.